PATENT CLAIM ANALYSIS

Application Number: 16110309
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["514", "04400A"]

Abstract:
The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.

Claim (Index 173):
The mRNA of  claim 165 , wherein the 5\u2032 UTR is at least 80% identical to the nucleotide sequence of SEQ ID NO: 33.

Metadata:
- Claim Count in Document: 119.0
- Percentile: 96.0
- Lexical Diversity: 1.8
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16002472', '16002376', '16110833', '15995889', '15996146']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8767427541245403
- 35 USC 102 Novelty (BERT): 0.6293986727078739
- Combined Prediction Score: 0.8520083459828737
- Mean Citation Score: 627.497762
- Max Citation Score: 694.53314
- Similarity Product: 522.5524392516899

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test